



# PHARMACY FACTS

*Current information for pharmacists about  
the MassHealth Pharmacy Program*

[www.mass.gov/masshealth-pharmacy-facts](http://www.mass.gov/masshealth-pharmacy-facts)

Editor: Vic Vangel

Contributors: Aimee Evers, Paul Jeffrey, Kim Lenz, Nancy Schiff, Vic Vangel

## MHDL Update

Below are certain updates to the MassHealth Drug List (MHDL). See the MHDL for a complete listing of updates.

### Additions

Effective December 10, 2018, the following newly marketed drugs have been added to the MHDL.

- Altreno (tretinoin 0.05% lotion) – **PA**
- Epidiolex (cannabidiol) – **PA**
- Fulphila (pegfilgrastim-jmdb) – **PA**
- Jivi (antihemophilic factor, recombinant pegylated-aucl)
- Lokelma (sodium zirconium cyclosilicate) – **PA > 30 units/month**
- Lucemyra (lofexidine) – **PA**
- Macrilen (macimorelin) ^
- Nivestym (filgrastim-aafi) – **PA**
- Orilissa (elagolix) – **PA**
- Palynziq (pegvaliase-pqpz) – **PA**
- Poteligeo (mogamulizumab-kpkc) – **PA**
- Tibsovo (ivosidenib) – **PA**
- Trivisc (hyaluronate) – **PA**

### Change in Prior-Authorization Status

- a. Effective December 10, 2018, the following antidiabetic agents will no longer require prior authorization.
  - Bydureon (exenatide extended-release pen, vial)
  - Byetta (exenatide)
  - Farxiga (dapagliflozin)

## Change in Prior-Authorization Status

(cont.)

- Invokamet (canagliflozin/metformin)
  - Invokana (canagliflozin)
  - Janumet (sitagliptin/metformin)
  - Janumet XR (sitagliptin/metformin extended-release)
  - Januvia (sitagliptin)
  - Jardiance (empagliflozin)
  - Jentadueto (linagliptin/metformin)
  - Kombiglyze XR (saxagliptin/metformin extended-release)
  - Onglyza (saxagliptin)
  - Tradjenta (linagliptin)
  - Xigduo XR (dapagliflozin/metformin extended-release)
- b. Effective December 10, 2018, the following hematopoietic agents will require prior authorization.
    - Granix (TBO-filgrastim) – **PA**
    - Zarxio (filgrastim-sndz) – **PA**
  - c. Effective December 10, 2018, the following enzyme cofactor agent will require prior authorization.
    - Kuvan (sapropterin) – **PA**

(cont.)

## Updated MassHealth Brand Name Preferred Over Generic Drug List

- a. Effective December 10, 2018, the following agents will be added to the MassHealth Brand Name Preferred Over Generic Drug List.
- Androgel (testosterone 1.62% gel packet, pump)<sup>BP</sup> – **PA**
  - Androgel (testosterone 1% gel packet)<sup>BP</sup> – **PA**
  - Byetta (exenatide)<sup>BP</sup>
  - Canasa (mesalamine suppository)<sup>BP</sup>
  - Epclusa (sofosbuvir/velpatasvir)<sup>BP</sup> – **PA**
  - Finacea (azelaic acid gel)<sup>BP</sup> – **PA**
  - Harvoni (ledipasvir/sofosbuvir)<sup>BP</sup> – **PA**
  - Latuda (lurasidone)<sup>BP</sup> – **PA**
  - Rapaflo (silodosin)<sup>BP</sup> – **PA**
  - Zytiga (abiraterone)<sup>BP</sup> – **PA**
- b. Effective December 10, 2018, the following agents will be removed from the MassHealth Brand Name Preferred Over Generic Drug List.
- Renvela # (sevelamer carbonate)
  - Tazorac (tazarotene) – **PA**

## Legend

- # Designates a brand-name drug with FDA “A”-rated generic equivalents. Prior authorization is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated generic equivalent.
- PA** Prior authorization is required. The prescriber must obtain prior authorization for the drug in order for the pharmacy to receive payment. Note: PA applies to both the brand-name and the FDA “A”-rated generic equivalent of listed product.
- BP** Brand preferred over generic equivalents. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing the nonpreferred drug generic equivalent.
- PD** Preferred drug. In general, MassHealth requires a trial of the preferred drug (PD) or a clinical rationale for prescribing a nonpreferred drug within a therapeutic class.
- ^** Drug available through the health care professional who administers the drug. MassHealth does not pay for this drug to be dispensed through a retail pharmacy.